뉴스

SNUH to spread advanced clinical trials capability in Saudi Arabia

2019-07-24
​July 2019

THE GREATS TIMES

The Seoul National University Hospital Clinical Trials Center
 

Publisher: In-Jin Jang MD, PhD, Director



SNUH to spread advanced clinical trials capability in Saudi Arabia

Execution of the agreement among SNUH-KAIMRC-KoNECT to train the clinical trials personnel


The signing ceremony at the Four Seasons Hotel Seoul. SNUH President and CEO,
Yon Su Kim (second from right) and KAIMRC CEO, Bandar Al Kanwy (second from the left).

Seoul National University Hospital (SNUH), King Abdullah International Medical Research Center (KAIMRC),
and Korea National Enterprise for Clinical Trials (KoNECT) signed an agreement to train researchers for clinical trials. Under this agreement,
SNUH will train approximately 80 KAIMRC clinical personnel about South Korea’s advanced clinical trials capability for two years.

The signing took place during the “Korea-Saudi Arabia Partnership Convention,” sponsored
by the Saudi Arabian General Investment Authority on June 26.

In particular, this agreement is meaningful as it is in accordance with Saudi’s national goal of “VISION 2030” to alleviate its crude-dependent economic structure
by expanding the healthcare and information technology (IT) industry.
The signing ceremony was held during Saudi Arabian Crown Prince Mohammed bin Salman’s visit to South Korea.

Dr. In-Jin Jang, the Clinical Trials Center Director of SNUH, said,
“This agreement is an example of Korea’s ability to perform clinical trials in the global market
and will serve as an opportunityto improve the capabilities of the pharmaceutical and bio-industry to the international level.
 



Collaboration on 14C-Microtracing and Microdosing research

MOU signed between SNUH and Biocore.

On February 25, SNUH and Biocore signed a memorandum of understanding (MOU) for clinical research on 14C-Microtracing and Microdosing.

The 14C-Microtracing and Microdosing are analytical techniques used to obtain information on absorption, distribution, metabolism,
and excretion of a drug by quantifying a trace amount of radioactive isotope 14C attached to the drug via Accelerator Mass Spectrometry (AMS).
These techniques allow the most accurate and costeffective clinical trials without any radiation exposure,
leading to a new paradigm in the development of new drugs by allowing researchers to obtain precise pharmacokinetic data.

These 14C-Microtracing and Microdosing technologies were first introduced in Korea by SNUH and Biocore.Dr. Howard Lee, a professor of Clinical Pharmacology,
has been pioneering the establish- ment of the Microtracing and Microdosing clinical trial platform at SNUH for the past four years.
Recently, clinical trial using 14C-Microtracing and Microdosing technologies was approved for an investigational new drug (IND) application by the Food and Drug Administration (FDA).
Altogether, these two organizations are expected to expand the scope of research.
 


A symposium to bring together clinical trials personnel in Korea

A picture during the symposium

Korea Association of Clinical Trials Center (KACTC) held a joint symposium with Korea National Enterprise for Clinical Trials (KoNECT)
on June 27 at the main auditorium of the Biomedical Research Institute, SNUH.
More than 170 attendees participated in lectures and iscussion on Institutional Review Board (IRB) and efficiency of clinical trials.

Since its establishment in 2006, KACTC has been continuously making effort to cooperate with 28 domestic clinical trials centers. urrently, Dr. In-Jin Jang,
director of SNUH CTC, is serving as the president.


If you have any inquiries, please contact:
Office of Global Strategy and Planning +82 2 2072 1684, snuhctcgsp@snuh.org